NVZMF (Novonesis (Novozymes) B) Total Long-Term Assets: $16,737 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMF Novonesis (Novozymes) B NVZMF
92 GF Score
Price $65.87
GF Value $63.81
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Total Long-Term Assets?

Novonesis (Novozymes) B NVZMF +6.75% 92 Total Long-Term Assets is $16,737 Mil as of Mar. 2026. GuruFocus rates NVZMF with a GF Score™ of 92/100 and a GF Value™ of $63.81 (Fairly Valued). The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Novonesis (Novozymes) B's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $16,737 Mil.

Novonesis (Novozymes) B Total Long-Term Assets Related Terms

Novonesis (Novozymes) B Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Novonesis (Novozymes) B's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novonesis (Novozymes) B Total Long-Term Assets Chart

Novonesis (Novozymes) B Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,574.30 2,664.62 2,769.79 13,943.67 16,821.90

Novonesis (Novozymes) B Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,174.59 16,550.40 16,838.50 16,821.90 16,737.11
NVZMF
92GF Score
Novonesis (Novozymes) B NVZMF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novonesis (Novozymes) B Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $16,737 Mil mean?
Novonesis (Novozymes) B (NVZMF) has a Total Long-Term Assets of $16,737 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Novonesis (Novozymes) B and its competitors.
Is Novonesis (Novozymes) B's Total Long-Term Assets too high?
Novonesis (Novozymes) B's current Total Long-Term Assets is $16,737 Mil. Overall, Novonesis (Novozymes) B has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Total Long-Term Assets compare to LIN and SHW?
Novonesis (Novozymes) B's Total Long-Term Assets of $16,737 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Chemicals company?
A good Total Long-Term Assets depends on the Chemicals industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Novonesis (Novozymes) B and its competitors. Novonesis (Novozymes) B's current Total Long-Term Assets is $16,737 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $63.81, compared to a current price of $65.87 — trading 3.2% above its estimated fair value. The current Total Long-Term Assets is $16,737 Mil. Novonesis (Novozymes) B's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current Total Long-Term Assets is $16,737 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $65.87 is trading 3.2% above its estimated GF Value™ of $63.81. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMF:

  • Total Long-Term Assets: $16,737 Mil
  • GF Value™: $63.81 vs. price of $65.87 (3.2% above fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
92GF Score

Get the complete analysis for NVZMF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$65.87
Price
$63.81
GF Value